Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cca.2021.03.031 http://scihub22266oqcxt.onion/10.1016/j.cca.2021.03.031 33826953!8019593!33826953     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Chim+Acta 2021 ; 519 (ä): 26-31 Nephropedia Template TP {{tp|p=33826953|t=2021. Clinical relevance of serum alpha-l-fucosidase activity in the SARS-CoV-2 infection |pdf=|usr=}}{{33826953}} gab.com Text Clinical relevance of serum alpha-l-fucosidase activity in the SARS-CoV-2 infection JO: Clin Chim Acta http://www.kidney.de/pget.php?&tw=1&pmid=33826953 #FOAvip BACKGROUND AND AIMS: The reduced fucosylation in the spike glycoprotein of SARS-CoV-2 and the IgG antibody has been observed in COVID-19. However, the clinical relevance of alpha-l-fucosidase, the enzyme for defucosylation has not been discovered. MATERIALS AND METHODS: 585 COVID-19 patients were included to analyze the correlations of alpha-l-fucosidase activity with the nucleic acid test, IgM/IgG, comorbidities, and disease progression. RESULTS: Among the COVID-19 patients, 5.75% were double-negative for nucleic acid and antibodies. All of them had increased alpha-l-fucosidase, while only one had abnormal serum amyloid A (SAA) and C-reactive protein (CRP). The abnormal rate of alpha-l-fucosidase was 81.82% before the presence of IgM, 100% in the presence of IgM, and 66.2% in the presence of IgG. 73.42% of patients with glucometabolic disorders had increased alpha-l-fucosidase activity and had the highest mortality of 6.33%. The increased alpha-l-fucosidase was observed in 55.8% of non-severe cases and 72.9% of severe cases, with an odds ratio of 2.118. The alpha-l-fucosidase mRNA was irrelevant to its serum activity. CONCLUSION: The change in alpha-l-fucosidase activity in COVID-19 preceded the IgM and SAA and showed a preferable relation with glucometabolic disorders, which may be conducive to virus invasion or invoke an immune response against SARS-CoV-2. Twit Text FOAVip Clinical relevance of serum alpha-l-fucosidase activity in the SARS-CoV-2 infection ????Clin Chim Acta http://www.kidney.de/pget.php?&tw=1&pmid=33826953 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33826953 #FOAvip English Wikipedia <ref>{{Cite pmid|33826953}}</ref> Clinical relevance of serum alpha-l-fucosidase activity in the SARS-CoV-2 infection #MMPMID33826953 Liang EY; Li GH; Wang WG; Qiu XM; Ke PF; He M; Huang XZ Clin Chim Acta 2021[Aug]; 519 (ä): 26-31 PMID33826953show ga BACKGROUND AND AIMS: The reduced fucosylation in the spike glycoprotein of SARS-CoV-2 and the IgG antibody has been observed in COVID-19. However, the clinical relevance of alpha-l-fucosidase, the enzyme for defucosylation has not been discovered. MATERIALS AND METHODS: 585 COVID-19 patients were included to analyze the correlations of alpha-l-fucosidase activity with the nucleic acid test, IgM/IgG, comorbidities, and disease progression. RESULTS: Among the COVID-19 patients, 5.75% were double-negative for nucleic acid and antibodies. All of them had increased alpha-l-fucosidase, while only one had abnormal serum amyloid A (SAA) and C-reactive protein (CRP). The abnormal rate of alpha-l-fucosidase was 81.82% before the presence of IgM, 100% in the presence of IgM, and 66.2% in the presence of IgG. 73.42% of patients with glucometabolic disorders had increased alpha-l-fucosidase activity and had the highest mortality of 6.33%. The increased alpha-l-fucosidase was observed in 55.8% of non-severe cases and 72.9% of severe cases, with an odds ratio of 2.118. The alpha-l-fucosidase mRNA was irrelevant to its serum activity. CONCLUSION: The change in alpha-l-fucosidase activity in COVID-19 preceded the IgM and SAA and showed a preferable relation with glucometabolic disorders, which may be conducive to virus invasion or invoke an immune response against SARS-CoV-2. |*COVID-19[MESH] |*SARS-CoV-2[MESH] |Antibodies, Viral[MESH] |Humans[MESH] |Immunoglobulin M[MESH]Clinical relevance of serum alpha-l-fucosidase activity in the SARS-Co(epmc).pdf DeepDyve Pubget Overpricing